At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4556 Gene Editing
Trading 12-23 12:24:29 EST
418.13
-2.89
-0.69%
High423.54Low412.92Vol6.31M
Open419.56D1 Closing421.02Amplitude2.52%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O56.11MT/O Rate--Tradable Shares0.00
P/B1.920966ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
5 Biotech Breakthrough Stocks to Watch in 2025
Zacks  ·  12-23 22:39
5 Biotech Breakthrough Stocks to Watch in 2025
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
Zacks  ·  12-23 20:49
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
Motley Fool  ·  12-23 00:25
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing
TIPRANKS  ·  12-21 01:58
CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing
Intellia Crashes 60% in a Year: How Should You Play the Stock?
Zacks  ·  12-21 01:57
Intellia Crashes 60% in a Year: How Should You Play the Stock?
1 big new Green Flag for CRISPR Therapeutics' Stock
Motley Fool  ·  12-20
1 big new Green Flag for CRISPR Therapeutics' Stock
Press Release: BLUE MOON METALS CLOSES C$30 MILLION IN EQUITY FINANCING WITH LEAD ORDERS FROM HARTREE PARTNERS, WHEATON PRECIOUS METALS AND LNS, AND SIGNS DEFINITIVE AGREEMENTS TO ACQUIRE TWO NORWEGIAN BROWNFIELD COPPER PROJECTS
Dow Jones  ·  12-20
Press Release: BLUE MOON METALS CLOSES C$30 MILLION IN EQUITY FINANCING WITH LEAD ORDERS FROM HARTREE PARTNERS, WHEATON PRECIOUS METALS AND LNS, AND SIGNS DEFINITIVE AGREEMENTS TO ACQUIRE TWO NORWEGIAN BROWNFIELD COPPER PROJECTS
Sector Update: Health Care Stocks Mixed Premarket Thursday
MT Newswires Live  ·  12-19
Sector Update: Health Care Stocks Mixed Premarket Thursday
Sangamo Shares Rally Premarket on License Deal With Astellas
Dow Jones  ·  12-19
Sangamo Shares Rally Premarket on License Deal With Astellas
Sangamo Grants Capsid License to Astellas for Neurological Disease Targets
MT Newswires Live  ·  12-19
Sangamo Grants Capsid License to Astellas for Neurological Disease Targets
BRIEF-Sangamo Therapeutics & Astellas Enter Capsid License Agreement
Reuters  ·  12-19
BRIEF-Sangamo Therapeutics & Astellas Enter Capsid License Agreement
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
THOMSON REUTERS  ·  12-19
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Sangamo Therapeutics Inc - to Receive $20 Million Upfront License Fee
THOMSON REUTERS  ·  12-19
Sangamo Therapeutics Inc - to Receive $20 Million Upfront License Fee
Sangamo Therapeutics Inc - Eligible for up to $1.3 Billion in Milestone Payments
THOMSON REUTERS  ·  12-19
Sangamo Therapeutics Inc - Eligible for up to $1.3 Billion in Milestone Payments
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Business Wire  ·  12-19
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Cathie Wood’s ARK Investment buys 116K shares of Beam Therapeutics today
TIPRANKS  ·  12-19
Cathie Wood’s ARK Investment buys 116K shares of Beam Therapeutics today
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
Zacks  ·  12-17
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Motley Fool  ·  12-17
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today
TIPRANKS  ·  12-17
Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today
Crispr Therapeutics call volume above normal and directionally bullish
TIPRANKS  ·  12-17
Crispr Therapeutics call volume above normal and directionally bullish

Introduction

Company Name.
BK4556
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--